SML4009
Zuclopenthixol decanoate
≥98% (HPLC)
别名:
Decanoic acid 2-[4-[(3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]-1-piperazinyl]ethyl ester
质量水平
方案
≥98% (HPLC)
表单
oil
颜色
, Colorless to light brown
储存温度
-10 to -25°C
SMILES字符串
ClC(C=C1)=CC2=C1SC3=CC=CC=C3/C2=C/CCN4CCN(CCOC(CCCCCCCCC)=O)CC4
InChI
1S/C32H43ClN2O2S/c1-2-3-4-5-6-7-8-15-32(36)37-24-23-35-21-19-34(20-22-35)18-11-13-27-28-12-9-10-14-30(28)38-31-17-16-26(33)25-29(27)31/h9-10,12-14,16-17,25H,2-8,11,15,18-24H2,1H3/b27-13-
InChI key
QRUAPADZILXULG-WKIKZPBSSA-N
生化/生理作用
Long-lasting injectable formulation (depot form) of Zuclopenthixol; potent antagonist of D1/D2 dopamine receptors, α1-adrenergic receptors and 5-HT2 receptors.
Zuclopenthixol decanoate is a long-lasting injectable formulation (depot form) of Zuclopenthixol. Zuclopenthixol decanoate is a potent antagonist of D1/D2 dopamine receptors, α1-adrenergic receptors and 5-HT2 receptors. Zuclopenthixol decanoate is approved in some countries for treatment of schizophrenia and other psychoses and recommended for patients who are agitated or aggressive.
Zuclopenthixol decanoate is a long-lasting injectable formulation (depot form) of Zuclopenthixol. Zuclopenthixol decanoate is a potent antagonist of D1/D2 dopamine receptors, α1-adrenergic receptors and 5-HT2 receptors. Zuclopenthixol decanoate is approved in some countries for treatment of schizophrenia and other psychoses and recommended for patients who are agitated or aggressive.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses
Cochrane database of systematic reviews (Online), 1999(2) (2000)
Matthew Cordiner et al.
Therapeutic advances in psychopharmacology, 6(2), 66-76 (2016-05-04)
Antipsychotic polypharmacy (APP) is common clinical practice. Theoretically, APP runs the risk of additional side effects, drug interactions, adherence and cost. A limited evidence base is emerging to support the effectiveness of APP in clinical practice. Our companion paper highlighted
Christoph U Correll et al.
CNS drugs, 35(1), 39-59 (2021-01-29)
The availability of long-acting injectable (LAI) antipsychotics for the treatment of schizophrenia provides clinicians with options that deliver continuous drug exposure and may improve adherence compared with daily oral antipsychotics. However, all LAI antipsychotics have unique formulations and pharmacokinetic characteristics
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持